Lumos Pharma, Inc. (LUMO)

Dec 12, 2024 - LUMO was delisted (reason: acquired by Double Point Ventures)
4.340
0.00 (0.00%)
Inactive · Last trade price on Dec 11, 2024
48.63%
Market Cap 37.54M
Revenue (ttm) 2.21M
Net Income (ttm) -34.92M
Shares Out 8.65M
EPS (ttm) -4.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 390,873
Open 4.330
Previous Close 4.340
Day's Range 4.330 - 4.340
52-Week Range 1.370 - 4.580
Beta 0.31
Analysts Buy
Price Target 9.38 (+116.13%)
Earnings Date Nov 7, 2024

About LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic f... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 33
Stock Exchange NASDAQ
Ticker Symbol LUMO
Full Company Profile

Financial Performance

In 2023, Lumos Pharma's revenue was $2.05 million, an increase of 34.67% compared to the previous year's $1.52 million. Losses were -$34.03 million, 9.57% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for LUMO stock is "Buy." The 12-month stock price forecast is $9.38, which is an increase of 116.13% from the latest price.

Price Target
$9.38
(116.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma

AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeu...

12 days ago - GlobeNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.

NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Lumos Pharma, Inc. (NASDAQ: LUMO) and its board of directors concerning the proposed ac...

2 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders

NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

Other symbols: MMLP
2 months ago - PRNewsWire

Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an update...

3 months ago - GlobeNewsWire

Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will...

4 months ago - GlobeNewsWire

Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript

Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Office...

5 months ago - Seeking Alpha

Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency

5 months ago - GlobeNewsWire

Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024

AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second qua...

5 months ago - GlobeNewsWire

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024

AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyse...

7 months ago - GlobeNewsWire

Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript

Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Officer ...

7 months ago - Seeking Alpha

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achiev...

7 months ago - GlobeNewsWire

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quart...

8 months ago - GlobeNewsWire

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) t...

8 months ago - GlobeNewsWire

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) t...

9 months ago - GlobeNewsWire

Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Conference March 7, 2024 4:30 PM ET Company Participants Lisa Miller - Vice President, IR Rick Hawkins - CEO and Chairman John McKew - President and ...

10 months ago - Seeking Alpha

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Mo...

10 months ago - GlobeNewsWire

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th...

10 months ago - GlobeNewsWire

Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference

AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency ...

11 months ago - GlobeNewsWire

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukchee...

1 year ago - GlobeNewsWire

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency ...

1 year ago - GlobeNewsWire

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Compan...

1 year ago - GlobeNewsWire

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 –

1 year ago - GlobeNewsWire

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3

1 year ago - GlobeNewsWire

Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency...

1 year ago - GlobeNewsWire

Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

AUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency...

1 year ago - GlobeNewsWire